The results were validated in bone marrow samples of CML patients, where a significant increase of AURKA, PLK1 and FOXM1 activating phosphorylation was associated with BCR-ABL1 TK and IM resistance (Fig. 3). Here, PLK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.